- Confirmation of the differential upregulation of miR-10b in GBM tumor cells compared to normal brain tissue and a panel of other normal and malignant cell types.
- Identification of highly potent and specific anti-miR-10b oligonucleotide compounds that inhibited the growth of human GBM cell lines in vitro and in vivo.
- Demonstration of significant synergy benefit with the Company's lead anti-miR-10b compound. Results showed efficacy as monotherapy (18% increase in median survival vs. control) comparable to standard of care temozolomide (27% increase in median survival) and synergy in combination with temozolomide ( >150% increased median survival; p = 0.0001) in an orthotopic tumor model in which human GBM cells were surgically implanted into mouse brains. Further details are available in the poster provided on Regulus' website.
"These results provide strong evidence that targeting miR-10b may provide therapeutic benefit in patients with GBM and supports the continued advancement of our program to address this cancer which has no highly effective therapy," said Dr.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Regulus to undertake certain activities and accomplish certain goals and objectives (including with respect to development and other activities related to its miR-10b program in GBM). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Regulus' financial position and programs are described in additional detail in Regulus filings with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/regulus-presents-preclinical-survival-data-highlighting-potential-of-novel-treatment-for-glioblastoma-multiforme-300752667.html
Dan Chevallard, Chief Financial Officer, 858-202-6376, email@example.com